MNPR
Monopar Therapeutics Inc (MNPR)
Healthcare • NASDAQ • $70.70+2.06%
- Symbol
- MNPR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $70.70
- Daily Change
- +2.06%
- Market Cap
- $464.95M
- Trailing P/E
- N/A
- Forward P/E
- -36.16
- 52W High
- $124.82
- 52W Low
- $50.07
- Analyst Target
- $129.92
- Dividend Yield
- 0.00%
- Beta
- 1.51
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targetin…
Company websiteResearch MNPR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.